Topic: liver damage

microscope image of nash

11. Ocaliva

While Intercept will be pleased that it gained a speedy FDA approval for Ocaliva in the liver condition primary biliary cholangitis—in combo with ursodeoxycholic acid—in the summer, it will be eyeing the potentially much bigger licence of non-alcoholic fatty liver disease, or NASH, as its main prize.

NIH scientists synthesize drug that limits liver fibrosis in mice

Liver fibrosis, a progressive scarring of the liver brought on by chronic alcoholism, viral hepatitis, obesity or diabetes that can lead to cirrhosis and cancer of the liver, currently has no mainstay treatment. Now researchers have reported developing a drug that limits liver fibrosis in mice.